조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C15H13NO3 · C4H11NO3
CAS 번호:
Molecular Weight:
376.40
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
ketorolac
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3
InChI
1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2
InChI key
BWHLPLXXIDYSNW-UHFFFAOYSA-N
Gene Information
human ... PTGS1(5742), PTGS2(5743)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ketorolac trometamol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Michel Weber et al.
Acta ophthalmologica, 91(1), e15-e21 (2012-09-14)
To determine whether indomethacin 0.1% eye drops are at least as effective as ketorolac 0.5% eye drops in treating ocular inflammation following cataract surgery. Prospective, multicenter, investigator-masked, parallel-group, randomized, active-controlled clinical trial. Cataract patients were randomized in a 1:1 ratio
Stephen J Kim et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 130(4), 456-460 (2012-04-12)
To investigate the adverse ocular effects of intravitreal ketorolac (4 mg) in patients with chronic uveitis and complications of chronic inflammation (macular edema). We conducted a prospective phase 1 clinical trial involving 10 eyes of 10 adult patients with chronic
V Pfaffenrath et al.
Cephalalgia : an international journal of headache, 32(10), 766-777 (2012-06-20)
Ketorolac is a non-triptan, non-opioid, mixed cyclooxygenase (COX)1/2-inhibitor for short-term management of moderate-to-severe acute pain. This trial evaluated an intranasal formulation of ketorolac tromethamine (SPRIX®) containing 6% lidocaine (ROX-828) for the acute treatment of migraine with and without aura as